Abstract:Zahlreiche entzündliche Dermatosen gehen mit der Ausschüttung proinflammatorischer Zytokine einher, die ihre Wirkung über den intrazellulären JAK‐STAT‐Mechanismus entfalten. JAK‐Inhibitoren stellen daher einen vielversprechenden zielgerichteten therapeutischen Ansatz für eine Vielzahl von Hauterkrankungen dar. In den letzten Jahren konnten mit diesen small molecules beeindruckende Wirkungen erzielt werden. Mit der Zulassung der JAK‐Inhibitoren Baricitinib, Upadacitinib und Abrocitinib stehen nun neue Systemtherapeutika für die mittelschwere bis schwere atopische Dermatitis zur Verfügung. Andere dermatologische Krankheiten, bei denen die Wirksamkeit der JAK‐Inhibitoren sowohl nach systemischer als auch topischer Applikation gezeigt werden konnte, sind Psoriasis, Chilblain‐Lupus, Dermatomyositis, Vitiligo und Alopecia areata. Für die Dermatologie sind damit eine ganze Reihe neuer Medikamentenzulassungen zu erwarten. In diesem Minireview möchten wir die Wirkprinzipien der JAK‐Inhibitoren erläutern, einen Überblick über bisherige Studienergebnisse bei verschiedenen entzündlichen Dermatosen geben und auch auf potenzielle unerwünschte Wirkungen und nötige Vor‐ sowie Kontrolluntersuchungen eingehen. Numerous chronic inflammatory skin diseases are associated with the release of proinflammatory cytokines, which work via the intracellular JAK‐STAT pathway. JAK inhibitors represent a promising, targeted therapeutic approach for cutaneous diseases. Impressive effects have been achieved with these agents in recent years. With the approval of the JAK1/2‐inhibitor baricitinib, a new systemic therapeutic agent is now available for moderate to severe atopic dermatitis. Other diseases in which the effectiveness of these small molecules could be shown are psoriasis, chilblain lupus, dermatomyositis, vitiligo and alopecia areata. As dermatologists, we are facing a whole series of new drug approvals. In this minireview we explain the active principles of JAK inhibitors and review study results in selected inflammatory skin diseases. Finally, possible side effects and initial as well as follow‐up laboratory examinations for these drugs are discussed.

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway

The JAK-STAT Pathway and the JAK Inhibitors

JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

[Janus kinase inhibitors for skin disorders]

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review

JAK/STAT and VEGF/PAK1 Signaling As Emerging Targets for Topical Treatment of Psoriasis: a Pilot Study.

Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis.

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease

Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions

JAK‐Inhibitoren in der Dermatologie – kleine Moleküle, große Wirkung? Übersicht über Wirkmechanismus, Studienergebnisse und mögliche unerwünschte Wirkungen

The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis

JAK Inhibitors in Psoriatic Disease

Analysis of patient experiences regarding JAK inhibitors for atopic dermatitis, psoriasis, alopecia areata, and vitiligo

Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis

JAK inhibitors in lichen planus: a review of pathogenesis and treatments